Actively Recruiting
Letermovir for Preventing Cytomegalovirus Recurrence in High-Risk Kidney and KidneyPancreas Transplant Patients Phase 3 Study of Oral Letermovir as Secondary Prevention After CMV Infection Treatment
Led by University of Wisconsin, Madison · Updated on 2026-06-11
90
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of letermovir in preventing the recurrence of cytomegalovirus CMV infection in adult patients who have received kidney or simultaneous kidneypancreas transplants and are considered high risk due to their CMV serostatus DR-. This study focuses on those who develop CMV viremia requiring treatment and who show a lack of cell-mediated immunity. The trial is conducted by the University of Wisconsin, Madison, and participants are expected to be involved for about six months. Participants will switch from treatment with ganciclovir derivatives to letermovir, taken as a 480 mg oral tablet once daily for 84 days. This change happens when the viral load drops below 500 IUmL during weekly standard care monitoring, which differs from usual care that waits for undetectable virus levels for two weeks. The study aims to reduce exposure to valganciclovir, which can cause myelosuppressive toxicity, and support the development of cell-mediated immunity. The main focus is on how well letermovir works as a secondary prevention after initial CMV treatment. During the study, participants will have weekly viral load monitoring as part of standard care. Researchers will assess the number of CMV replication episodes above 1000 IUmL up to 90 days after stopping secondary prophylaxis, as well as the duration of valganciclovir treatment up to two months. Cell-mediated immunity will be measured using a specific T-Cell Immunity Panel test at the start of letermovir treatment and again around week 12. Safety, adherence, and immune response will be closely monitored throughout the approximately six-month study period.
CONDITIONS
Brief Title
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Research Team
S
Sandesh Parajuli, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here